Clear Street Initiates Coverage of Caribou Biosciences with Buy Recommendation and Projects 659.76% Upside

Clear Street initiates coverage of Caribou Biosciences (CRBU) with a Buy recommendation, with an average one-year price target of $11.09/share, representing a 659.76% increase from its latest closing price. The projected annual revenue is 56MM, an increase of 503.55%, and the projected annual non-GAAP EPS is -1.58. There are 177 funds or institutions reporting positions in CRBU, with Pfizer holding 4,690K shares representing 5.02% ownership.